Defendant
2 cases as defendant.
Eugia Pharma Specialities Ltd. (also written "Eugia Pharma Specialties"; the company itself uses both spellings) is a pharmaceutical manufacturer headquartered in Hyderabad, Telangana, India. It was incorporated in 2013 as a joint venture between Aurobindo Pharma Ltd. and Sequoia-backed Celon Laboratories to develop hormonal and oncology generics. Aurobindo acquired the remaining 32.18% held through MViyeS Pharma Ventures in October 2020 for Rs 274.22 crore, making Eugia a wholly owned subsidiary of Aurobindo Pharma Ltd. (NSE/BSE: AUROPHARMA). Eugia is not separately listed; Aurobindo's website states Eugia employs over 4,000 staff worldwide (third-party trackers list roughly 2,000). No standalone revenue is disclosed.
Products / operations. Eugia houses Aurobindo's specialty injectables and oncology business, consolidated into it from 2020–2021. Its portfolio covers penems, penicillins, cephalosporins, ophthalmic and inhalation (respule) products, oncology and hormone products, in formats including vials, ampoules, bags, pre-filled syringes, cartridges, pen products, tablets and capsules. It operates several USFDA-registered formulation plants in Telangana, Andhra Pradesh and Rajasthan, markets in the US through Eugia US LLC, and reports 184 ANDA approvals from Eugia group facilities, including generics of Pomalyst (pomalidomide), Zortress (everolimus), icatibant, plerixafor and posaconazole. FDA inspections of its Telangana and Bhiwadi units have drawn Official Action Indicated classifications and warning letters (2024–2026).
Litigation posture. Eugia is an operating company, not an NPE: 0 plaintiff cases and 1 defendant case in the tracked data. Its appearances are Hatch-Waxman ANDA disputes brought by brand manufacturers, consistent with a generic-drug manufacturer rather than a patent assertor. The single tracked case sits in the District of New Jersey, a standard venue for such filings, not an NPE-favored venue like the Eastern District of Texas.
Notable case. Celgene Corp. v. Hetero Labs Ltd. et al., No. 2:17-cv-03387 (D.N.J., filed May 11, 2017), consolidated Celgene's patent claims over generic pomalidomide (Pomalyst) against Hetero, Aurobindo/Eugia, Apotex, Mylan, Breckenridge and Teva; a consent judgment was entered in August 2021 as to some defendants. Public dockets show Eugia/Aurobindo named in numerous other later D.N.J. Hatch-Waxman suits (e.g., Aragon, Theravance), but those are not in our tracked list.
Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).
Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.